RVL Pharmaceuticals plc (RVLP)

Market Cap	111.48M
Revenue (ttm)	49.72M
Net Income (ttm)	-51.69M
Shares Out	106.17M
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,195
Open	1.00
Previous Close	1.02
Day's Range	1.00 - 1.09
52-Week Range	0.98 - 2.99
Beta	1.10
Analysts	Buy
Price Target	3.76 (+258.1%)
Earnings Date	May 11, 2023

About RVLP

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 156
• Stock Exchange: NASDAQ
• Ticker Symbol: RVLP

Financial Performance

In 2022, RVLP's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.

Analyst Forecast

According to 11 analysts, the average rating for RVLP stock is "Buy." The 12-month stock price forecast is $3.76, which is an increase of 258.10% from the latest price.

Price Target

$3.76

(258.10% upside)

Analyst Consensus: Buy